Novartis to sell GW cannabis drug in some markets

LONDON, Apr 11 (The Economic Times): GW Pharmaceuticals has signed up Novartis to sell its cannabis-based drug Sativex in a range of markets, marking a key endorsement for the treatment from the major Swiss pharmaceutical company. GW said Novartis will file and market the GW Pharmaceuticals has signed up Novartis to sell its cannabis-based drug Sativex in a range of markets, marking a key endorsement for the treatment from the major Swiss pharmaceutical company. Drug, which has been approved in some European countries and Canada as a treatment for spasticity due to multiple sclerosis (MS), in Australia and New Zealand, Asia -- excluding Japan, China and Hong Kong --, the Middle East and Africa.